MediWound Ltd. (MDWD)
NASDAQ (NMS) NASDAQ (NMS) Primary 
XFRA 
MediWound Q1 Earnings Call Highlights
MediWound NASDAQ: MDWD reported a wider first-quarter loss and lower revenue compared with the prior-year period, while management reaffirmed its 2026 revenue outlook and said it continued to advance its EscharEx and NexoBrid programs.
MediWound (MDWD) Reports Q1 Loss, Misses Revenue Estimates
MediWound (MDWD) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.65. This compares to a loss of $0.07 per share a year ago.
MediWound Ltd. (MDWD) Q4 2025 Earnings Call Transcript
MediWound Ltd. (MDWD) Q4 2025 Earnings Call Transcript
MediWound (MDWD) Reports Q4 Loss, Lags Revenue Estimates
MediWound (MDWD) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus Estimate of a loss of $0.65. This compares to a loss of $0.36 per share a year ago.
MediWound Ltd. (MDWD) Q3 2025 Earnings Call Transcript
MediWound Ltd. ( MDWD ) Q3 2025 Earnings Call November 20, 2025 8:30 AM EST Company Participants Ofer Gonen - Chief Executive Officer Hani Luxenburg - Chief Financial Officer Barry Wolfenson - Executive Vice President of Strategy & Corporate Development Conference Call Participants Daniel Ferry - Lifesci Advisors, LLC Joshua Jennings - TD Cowen, Research Division Swayampakula Ramakanth - H.C.
MediWound (MDWD) Reports Q3 Loss, Misses Revenue Estimates
MediWound (MDWD) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.81. This compares to a loss of $0.98 per share a year ago.
MediWound Is A Buy Opportunity On The Dip
MediWound is a niche biotech with strong R&D, FDA-approved products, and a promising pipeline, but remains underfollowed and volatile. Despite weak current performance and negative metrics, the company has a solid cash runway, no debt, and recent strategic investments. NexoBrid's expanded approvals and rising hospital orders, plus a new facility, position MediWound for significant revenue growth in burn care.
MediWound Ltd. (MDWD) Q2 2025 Earnings Call Transcript
MediWound Ltd. (NASDAQ:MDWD ) Q2 2025 Earnings Conference Call August 14, 2025 8:30 AM ET Company Participants Barry J.
MediWound (MDWD) Reports Q2 Loss, Beats Revenue Estimates
MediWound (MDWD) came out with a quarterly loss of $1.23 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to a loss of $0.68 per share a year ago.
MediWound Ltd. (MDWD) Q1 2025 Earnings Call Transcript
MediWound Ltd. (NASDAQ:MDWD ) Q1 2025 Earnings Conference Call May 21, 2025 8:30 AM ET Company Participants Dan Ferry - LifeSci Advisors Ofer Gonen - CEO Hani Luxenburg - CFO Barry Wolfenson - EVP of Strategy and Corporate Development Conference Call Participants Chase Knickerbocker - Craig-Hallum RK - H.C.
MediWound (MDWD) Reports Q1 Loss, Misses Revenue Estimates
MediWound (MDWD) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.65. This compares to loss of $0.39 per share a year ago.
MediWound Ltd. (MDWD) Q4 2024 Earnings Call Transcript
MediWound Ltd. (NASDAQ:MDWD ) Q4 2024 Results Conference Call March 19, 2025 8:30 AM ET Company Participants Dan Ferry - IR, LifeSci Advisors Ofer Gonen - Chief Executive Officer Hani Luxenburg - Chief Financial Officer Barry Wolfenson - Executive Vice President, Strategy & Corporate Development Conference Call Participants Josh Jennings - Cowen Francois Brisebois - Oppenheimer RK - H.C.
